|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 676.69 USD | -0.33% |
|
+1.83% | -12.33% |
| 07-16 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
| 07-15 | Alnylam Initiates Mid-Stage Study of Mivelsiran in Down Syndrome-Associated Alzheimer's | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bearish | Neutral |
| Resistance | 686.36 | 686.36 | 803.17 |
| Spread/Res. | -1.41% | -1.41% | -15.75% |
| Spread/Supp. | +6.49% | +12.66% | +20.84% |
| Support | 635.45 | 600.66 | 560 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- REGN Stock
- Charts Regeneron Pharmaceuticals, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
